Entacapone
(Synonyms: 恩他卡朋) 目录号 : GC17334
Entacapone是一种有效的、可逆的、外周作用和具有口服活性的儿茶酚-O-甲基转移酶（COMT）抑制剂，可有效抑制大鼠肝脏总COMT，IC50和Ki值分别为20.1nM和10.7nM。
Cas No.:130929-57-6
Sample solution is provided at 25 µL, 10mM.
Entacapone is a potent, reversible, peripherally acting and orally active inhibitor of catechol-O-methyltransferase (COMT), which effectively inhibits rat liver total COMT with IC50 and Ki values of 20.1nM and 10.7nM, respectively[1]. Entacapone has IC50 values of 14.3nM and 73.3nM for rat liver soluble COMT (S-COMT) and rat liver membrane-bound COMT (MB-COMT), respectively[1]. Entacapone is a weak uncoupler of oxidative phosphorylation[2]. Entacapone is commonly used in combination with levodopa (L-DOPA) to treat Parkinson's disease[3]. Entacapone is a ferroptosis inhibitor that can enhance antioxidant capacity[4].
In vitro, treatment of esophageal cancer cell lines (KYSE-30 and YM-1 cells) with Entacapone (25-150μM) for 48h reduced cell viability in a dose-dependent manner, and induced apoptosis and altered the cell cycle at a concentration of 140μM[5]. Treatment of Hep-G2 cells with Entacapone (50μM) for 48h increased the amount of m6A on mRNA in cells[6].
In vivo, oral treatment of C57BL/6J mice with Entacapone (10, 50, 200mg/kg/day) for 21 days significantly improved ANA-12-induced memory impairment and the reduction of hippocampal brain-derived neurotrophic factor (BDNF) and tyrosine kinase receptor B (TrkB) expression, and significantly increased the number of Ki67-positive proliferating cells, doublecortin-positive immature neurons, and phosphorylated cAMP response element binding protein (pCREB)-positive cells in the dentate gyrus of the hippocampus[7]. Oral treatment of C57BL/6J mice with Entacapone (50mg/kg) for 21 days induced changes in the expression of proteins involved in synaptic transmission, cellular processes, cell signaling, cytoskeletal structure regulation, energy metabolism, and various other cellular responses in the mouse hippocampus[8].
References:
[1] Forsberg M, Lehtonen M, Heikkinen M, et al. Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat[J]. Journal of Pharmacology and Experimental Therapeutics, 2003, 304(2): 498-506.
[2] Nissinen E, Kaheinen P, Penttilä K E, et al. Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson's disease, does not impair mitochondrial energy production[J]. European journal of pharmacology, 1997, 340(2-3): 287-294.
[3] Stocchi F, Rascol O, Kieburtz K, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE‐PD study[J]. Annals of neurology, 2010, 68(1): 18-27.
[4] Yang J, Sun X, Huang N, et al. Entacapone alleviates acute kidney injury by inhibiting ferroptosis[J]. The FASEB Journal, 2022, 36(7): e22399.
[5] Ramedani F, Jafari S M, Saghaeian Jazi M, et al. Anti‐cancer effect of entacaponeon esophageal cancer cells via apoptosis induction and cell cycle modulation[J]. Cancer Reports, 2023, 6(3): e1759.
[6] Peng S, Xiao W, Ju D, et al. Identification of entacapone as a chemical inhibitor of FTO mediating metabolic regulation through FOXO1[J]. Science Translational Medicine, 2019, 11(488): eaau7116.
[7] Yoo D Y, Jung H Y, Kim W, et al. Entacapone promotes hippocampal neurogenesis in mice[J]. Neural Regeneration Research, 2021, 16(6): 1005-1010.
[8] Yoo D Y, Jung H Y, Kim W, et al. Entacapone treatment modulates hippocampal proteins related to synaptic vehicle trafficking[J]. Cells, 2020, 9(12): 2712.
Entacapone是一种有效的、可逆的、外周作用和具有口服活性的儿茶酚-O-甲基转移酶（COMT）抑制剂，可有效抑制大鼠肝脏总COMT，IC50和Ki值分别为20.1nM和10.7nM[1]。Entacapone对大鼠肝可溶性COMT（S-COMT）和大鼠肝膜结合COMT（MB-COMT）的IC50值分别为14.3nM和73.3nM[1]。Entacapone是一种弱的氧化磷酸化解偶联剂[2]。Entacapone通常与左旋多巴 （L-DOPA）联合使用来治疗帕金森病[3]。Entacapone是一种铁死亡抑制剂，能够增强抗氧化能力[4]。
在体外，Entacapone（25-150μM）处理食管癌细胞系（KYSE-30和YM-1细胞）48h，均剂量依赖性地降低了细胞活力，浓度为140μM时可诱导细胞凋亡并改变了细胞周期[5]。Entacapone（50μM）处理Hep-G2细胞48h，增加了细胞中mRNA上m6A的量[6]。
在体内，Entacapone（10, 50, 200mg/kg/day）通过口服治疗C57BL/6J小鼠21天，显著改善了ANA-12诱导的记忆障碍以及海马脑源性神经营养因子（BDNF）和酪氨酸激酶受体B（TrkB）表达的减少，显著增加了海马齿状回Ki67阳性增殖细胞、双皮质素阳性未成熟神经元和磷酸化cAMP反应元件结合蛋白（pCREB）阳性细胞的数量[7]。Entacapone（50mg/kg）通过口服治疗C57BL/6J小鼠21天，诱导了小鼠海马参与突触传递、细胞过程、细胞信号传导、细胞骨架结构调节、能量代谢和各种其他细胞反应的蛋白质表达变化[8]。
| Cell experiment [1]: | |
Cell lines | KYSE-30 and YM-1 of esophageal squamous cancer cell (ESCC) lines |
Preparation Method | Cells were seeded into 96-well plates at a density of 104 cells/well, the culture medium was removed and then cells were treated with different concentrations (25, 50, 75, 100, 125, and 150μM) of Entacapone with a final volume of 200μl. As vehicle control cells were treated with DMSO (0.3%) with same condition. After 48h treatment, cell viability was measured using the MTT assay. |
Reaction Conditions | 25-150μM; 48h |
Applications | Entacapone was cytotoxic to both esophageal cancer cell lines in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | C57BL/6J mice |
Preparation Method | Mice (n=10 per group) were randomly divided into four groups: the vehicle-treated control group and the groups treated with 10, 50, or 200mg/kg Entacapone. Vehicle or Entacapone was orally administered to the mice once a day using a feeding needle and ANA-12 was injected into the hippocampus at a rate of 0.5μL/min for 5min. Administered Entacapone for 21 days. Immunohistochemical staining was used to analyze the number of Ki67-positive proliferating cells, doublecortin-positive immature neurons and phosphorylated cAMP response element binding protein (pCREB)-positive cells in the dentate gyrus of the hippocampus of mice. |
Dosage form | 10, 50, 200mg/kg/day for 21 days; p.o. |
Applications | After Entacapone treatment, the numbers of Ki67-positive proliferating cells, doublecortin-positive immature neurons, and phosphorylated cAMP response element-binding protein (pCREB)-positive cells were significantly increased. |
References: [1]Ramedani F, Jafari S M, Saghaeian Jazi M, et al. Anti‐cancer effect of entacaponeon esophageal cancer cells via apoptosis induction and cell cycle modulation[J]. Cancer Reports, 2023, 6(3): e1759. [2]Yoo D Y, Jung H Y, Kim W, et al. Entacapone promotes hippocampal neurogenesis in mice[J]. Neural Regeneration Research, 2021, 16(6): 1005-1010. | |
| Cas No. | 130929-57-6 | SDF | |
| 别名 | 恩他卡朋 | ||
| 化学名 | (E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide | ||
| Canonical SMILES | CCN(CC)C(=O)C(=CC1=CC(=C(C(=C1)O)O)[N+](=O)[O-])C#N | ||
| 分子式 | C14H15N3O5 | 分子量 | 305.29 |
| 溶解度 | 60mg/mL in DMSO, ≥ 12.65 mg/mL in EtOH with ultrasonic | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.2756 mL | 16.3779 mL | 32.7557 mL |
| 5 mM | 0.6551 mL | 3.2756 mL | 6.5511 mL |
| 10 mM | 0.3276 mL | 1.6378 mL | 3.2756 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet